Yale University — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Yale University appears in 664 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials664

Recruiting shown60

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)NCT06996652 · lead sponsor · 2026-08-17

Leveraging Chatbot to Improve PrEP in the Southern United StatesNCT05968755 · lead sponsor · 2026-07-13

The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseNCT07610369 · lead sponsor · 2026-07-10

Promoting Palliative Care for People With Heart FailureNCT06933875 · lead sponsor · 2026-07-02

Evaluation of a Mobile App Program for Coping With CancerNCT06923501 · lead sponsor · 2026-06-11

Music for Pain and DementiaNCT07602283 · lead sponsor · 2026-06-09

Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of LifeNCT07376655 · lead sponsor · 2026-06-04

Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaNCT05917210 · lead sponsor · 2026-03-16

Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health ClinicsNCT06684613 · lead sponsor · 2026-03-11

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal SyndromeNCT07273838 · lead sponsor · 2026-03-05

Digital Mindfulness for Young Adults With Type 1 DiabetesNCT07062887 · lead sponsor · 2026-02-04

Iadademstat + SBRT With Atezo in ES-SCLCNCT07113691 · lead sponsor · 2026-01-20

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 SemaglutideNCT07040592 · lead sponsor · 2026-01-15

Saci Nivo Rela for TNBCNCT06963905 · lead sponsor · 2025-12-29

OPTImizing Malaria And HIV Treatment in a Shifting Landscape in AfricaNCT06967519 · lead sponsor · 2025-12-18

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine TherapyNCT06917313 · lead sponsor · 2025-12-05

Shared Decision Making to Treat Or Prevent (STOP) HIV in Criminal Legal Involved Populations (R33)NCT07223398 · lead sponsor · 2025-11-24

New Mechanisms of ObesityNCT06768827 · lead sponsor · 2025-11-13

Reducing Stigma in People Who Inject Drugs (PWID) With HIV Using a Rapid Start Antiretroviral Therapy Intervention (ART)NCT06541028 · lead sponsor · 2025-11-04

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBCNCT07066189 · lead sponsor · 2025-10-17

A Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart FailureNCT06671015 · lead sponsor · 2025-10-04

Exploring Water-free Sodium StorageNCT06872645 · lead sponsor · 2025-10-03

Circulating Tumor DNANCT06923527 · lead sponsor · 2025-09-30

T1CARE: A Trial of a Novel Intervention to Address Social Determinants of Health in Young Adults With Type 1 DiabetesNCT07059806 · lead sponsor · 2025-09-05

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes ScreeningNCT07155252 · lead sponsor · 2025-08-26

Building and Sustaining Exercise Habits for Adults With Type 1 DiabetesNCT06967701 · lead sponsor · 2025-07-10

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyNCT06953882 · lead sponsor · 2025-07-09

Trial of Trastuzumab Deruxtecan in Previously Treated HER2NCT06750484 · lead sponsor · 2025-06-20

Regulation of Brain Glucose Metabolism in Type 1 DiabetesNCT05317455 · lead sponsor · 2025-05-13

Exploring the Utility of [18F]3F4AP for Demyelination ImagingNCT06999434 · lead sponsor · 2025-05-05

Stress and Pain in People Living With HIVNCT06784908 · lead sponsor · 2025-01-16

HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)NCT06513819 · lead sponsor · 2025-01-15

Craving Network NeurofeedbackNCT06426693 · lead sponsor · 2024-11-27

Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM AccessNCT06658067 · lead sponsor · 2024-11-12

PRIDE III Prison Interventions and HIV Prevention CollaborationNCT06962033 · lead sponsor · 2024-11-05

Open-Label Psilocybin Study in Transdiagnostic PopulationNCT06442423 · lead sponsor · 2024-10-17

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant TherapyNCT05989347 · lead sponsor · 2024-10-15

Genetic Basis of the Risk and Consequences of Cannabis Exposure in HumansNCT06058702 · lead sponsor · 2024-09-16

Imaging Depression in Parkinson's DiseaseNCT06402955 · lead sponsor · 2024-09-01

Mechanisms of Diuretic Resistance in Heart Failure, Aim 3NCT06209359 · lead sponsor · 2024-07-24

Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)NCT05776563 · lead sponsor · 2024-07-19

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity TreatmentNCT06411210 · lead sponsor · 2024-07-16

Glu-COACH: a Peer-mentoring Intervention to Reduce Disparities in Continuous Glucose Monitor (CGM) UseNCT06171412 · lead sponsor · 2024-05-21

The SUGAR Study; SBRT and Relugolix) for Prostate CancerNCT06111781 · lead sponsor · 2024-04-15

PRESSURE CHECK: Find Your Path to Better HealthNCT06122246 · lead sponsor · 2024-04-14

Peru Decentralized HIV CareNCT05910268 · lead sponsor · 2024-04-01

The OBSERVE ProtocolNCT06725277 · lead sponsor · 2024-01-21

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCNCT06100705 · lead sponsor · 2023-12-20

Mechanisms of Ultrasound Neuromodulation Effects in DiabetesNCT06042517 · lead sponsor · 2023-09-30

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine ResponseNCT05915013 · lead sponsor · 2023-09-07

Mechanisms of Diuretic Resistance in Heart Failure, Aim 2NCT05753059 · lead sponsor · 2023-08-10

Expanding Medication-Assisted Therapies in Central AsiaNCT05579470 · lead sponsor · 2023-08-07

Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved WomenNCT05547048 · lead sponsor · 2023-07-25

Trauma-informed Approach to Timely Detection and Management of Early Postpartum HypertensionNCT05884190 · lead sponsor · 2023-06-12

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral TherapyNCT05586581 · lead sponsor · 2023-05-17

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal EffectsNCT05786066 · lead sponsor · 2023-04-03

Ultrasound Effects on Glycemic Control in T2DMNCT05354947 · lead sponsor · 2022-11-01

Intestinal Immunity in Neurologic DiseaseNCT06329453 · lead sponsor · 2022-08-02

Identifying and Characterizing Preclinical MSNCT05787795 · lead sponsor · 2022-06-21

Mechanisms of Diuretic Resistance in Heart Failure, Aim 1NCT05323487 · lead sponsor · 2022-06-01

Drugs studied in this sponsor's trials

123 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Yale University as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

ketamine9

naltrexone6

buprenorphine4

carboplatin4

paclitaxel4

cannabidiol3

cyclophosphamide3

glycine3

ketamine RxCUI 6130 · Lead sponsor in 8 linked trial(s) · 2 currently recruiting 9 trials naltrexone RxCUI 7243 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 6 trials buprenorphine RxCUI 1819 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 4 trials carboplatin RxCUI 40048 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 4 trials paclitaxel RxCUI 56946 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials cannabidiol RxCUI 2045371 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials glycine RxCUI 4919 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials bupropion RxCUI 42347 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials exenatide RxCUI 60548 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials furosemide RxCUI 4603 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials irinotecan hydrochloride RxCUI 153329 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials liraglutide RxCUI 475968 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials lisdexamfetamine dimesylate RxCUI 673579 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials metformin RxCUI 6809 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials nivolumab RxCUI 1597876 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials perampanel RxCUI 1356552 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials raltegravir RxCUI 719872 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials riluzole RxCUI 35623 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials semaglutide Pen Injector RxCUI 1991305 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials sorafenib RxCUI 495881 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials tamoxifen citrate RxCUI 40137 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials torsemide RxCUI 38413 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials trastuzumab RxCUI 224905 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials

Sponsor roles

lead sponsor538

collaborator126

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.